An international clinical trial testing LTI-03, Rein Therapeutics’ inhaled treatment candidate for idiopathic pulmonary fibrosis (IPF), is now recruiting participants at sites in five countries. The Phase 2 trial, dubbed RENEW (NCT06968845), aims to enroll approximately 120 people with IPF, ages 40 and older. Eligible participants will…
Managing the medical costs associated with chronic illness
Rehabilitation from serious health setbacks is hard. This week has repeatedly proven that to me. Since being diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I’ve learned a lot about the disease. But I haven’t learned everything yet. During my IPF journey, I wasn’t hospitalized after my…
The oral therapy Jascayd (nerandomilast) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The marketing authorization from the European Commission follows a positive recommendation from a regulatory committee and marks the first new IPF therapy approved…
When my husband and I decided to move to a small farm, we imagined early mornings feeding chickens, tending the garden together, and watching cattle graze in the distance. It wasn’t simply a place to live. It was the life we had dreamed of building. No one imagines that one day their own body will…
I’m home, at last, after a 17-day hospital stay where I was treated for shingles. Oddly enough, after it was determined by my care team that I was a viable candidate for a lung transplant following my diagnosis of idiopathic pulmonary fibrosis (IPF) in January 2017, I was…
The Pulmonary Fibrosis Foundation (PFF), an advocacy group dedicated to advancing care for people with pulmonary fibrosis, has added two new members to its board of directors. Both new board members are physicians with extensive experience caring for people with pulmonary fibrosis, which causes scarring in the lungs,…
Have you ever wondered what a columnist for Pulmonary Fibrosis News does while being hospitalized for 17 days? First, I focused on getting better. Second, I asked many questions of those caring for me. Finally, as I met other medical specialists, I asked them what they knew about…
Celea Therapeutics received $180 million in financing to develop deupirfenidone (LYT-100), an investigational therapy that the company says has the potential to serve as a new standard of care for people with idiopathic pulmonary fibrosis (IPF). The funding will support the planned launch of SURPASS-IPF (NCT07284602), a…
I feel like I’m in a long scene from the classic movie “The Neverending Story,” and the dark force is shingles. As I write this, I’m still hospitalized while my care team works to address the complications of this infection in a post-transplant patient. I’m determined to write this…
